Michael Sidler
Co-Founder & Partner @ redalpine
Zurich, Switzerland
Michael Sidler is a seed investor at redalpine in Zurich focused on Health Care and Biotechnology. Passionate investor, coach and supporter of startups and the whole ecosystem around them. GP at Redalpine
- Total investments:
- 15
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries Michael Sidler invests in
Stages Michael Sidler invests in
Countries Michael Sidler invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (20%)
- Biotechnology 3 (20%)
- Wellness 2 (13%)
- Therapeutics 2 (13%)
- Medical Device 2 (13%)
Stage
- Seed 4 (27%)
- Series A 3 (20%)
- Series B 2 (13%)
- Venture - Series Unknown 2 (13%)
- Series C 1 (7%)
Country
- Switzerland 3 (20%)
- Germany 2 (13%)
- United Kingdom 2 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Valink Therapeutics is a health care drug discovery for next-generation cancer treatments. | $11.8M / Seed / Oct 20, 2025 | ||
| Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $42M / Series B / May 01, 2025 | ||
| Dunia Innovation is a creating the world's first self-driving laboratory for electrocatalytic CO2 utilization, which will drastically accelerate catalyst research. | $11.5M / Venture - Series Unknown / Oct 23, 2024 | ||
| Dunia Innovation is a creating the world's first self-driving laboratory for electrocatalytic CO2 utilization, which will drastically accelerate catalyst research. | Seed / Oct 23, 2024 | ||
| ExpressionEdits operates in the biotechnology industry, focusing on the redesign of synthetic DNA instructions. The company utilizes an AI-driven approach to redefine the status quo of protein expression. It is involved in building biology similar to nature. The team at ExpressionEdits includes scientists and engineers who are dedicated todeveloping new technologies. Proteins, a foundational pillar in healthcare and behind every major advancement in biotech and synthetic biology, are at the core of their work. | $13M / Seed / May 29, 2024 | ||
| Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $30.7M / Series A / Feb 27, 2024 | ||
| Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $32.7M / Series D / Mar 23, 2023 | ||
| Sanity Group is a holistic European Cannabis company focusing on health, wellbeing, and scientific research. To utilize the full potential of its health benefits, Sanity Group is investing in fundamental research of the cannabis plant and its active ingredients as well as in specific areas of application.It was founded in 2018 and headquarteredin Berlin, Germany. | $37.6M / Series B / Sep 07, 2022 | ||
| Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $17.5M / Series A / Nov 02, 2021 | ||
| Sanity Group is a holistic European Cannabis company focusing on health, wellbeing, and scientific research. To utilize the full potential of its health benefits, Sanity Group is investing in fundamental research of the cannabis plant and its active ingredients as well as in specific areas of application.It was founded in 2018 and headquarteredin Berlin, Germany. | $44.2M / Series A / Jun 15, 2021 | ||
| See all 15 investments → | |||
Co-Investors
About redalpine
redalpine is the pan-European venture capital firm that empowers GameChangers. Founded in Zurich in 2006, with offices in Berlin, London, and a presence in San Francisco, redalpine brings together financial investment, operational expertise, and a vast international network to help ambitious entrepreneurs transform their vision into a reality. redalpine has over $1bn in assets under management and has backed some of Europe’s most disruptive software and science companies, including N26, Proxima Fusion, 9fin, Mistral, Klarna, Taxfix, and Aktiia. With a multi-stage investment approach, redalpine invests Europe-wide and counts over 100 companies in its portfolio. Find out more at www.redalpine.com
redalpine Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniel Dillinger
Principal
|
|||
Gianmarco Hodel
Associate
|
|||
Harald Nieder
General Partner
|
|||
|
Michael Sidler
Co-Founder & Partner
|
|||
Michelle Kuepper
Head of Communications; Head of Communications
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Sidler invest in?
Michael Sidler invests primarily in Health Care, Biotechnology and Wellness startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michael Sidler?
Public channels for Michael Sidler include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michael Sidler last invest?
The most recent investment recorded for Michael Sidler closed in Oct 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
